منابع مشابه
Brain metastases: the HER2 paradigm.
Between 100,000 and 170,000 patients with cancer develop central nervous system (CNS) metastases each year in the U.S., of which approximately 20% carry a primary diagnosis of breast cancer. As a consequence of improvements in systemic therapy, which have allowed patients to live longer with advanced cancer, CNS metastases are emerging as an important sanctuary site, and the incidence may be in...
متن کاملTargeting HER2 in brain metastases from breast cancer.
For many types of cancers, therapy aimed at a specific molecular target remains in the realm of clinical research. However, for breast cancer, rational therapeutics is routinely practiced in the clinic. For many years, oncologists have used tamoxifen to selectively treat women with estrogen receptorpositive breast cancer. Clinicians now screen breast cancer for HER2 overexpression, which occurs...
متن کاملCombined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Brain metastases are a serious obstacle in the treatment of patients with human epidermal growth factor receptor-2 (HER2)-amplified breast cancer. Although extracranial disease is controlled with HER2 inhibitors in the majority of patients, brain metastases often develop. Because these brain metastases do not respond to therapy, they are frequently the reason for treatment failure. We developed...
متن کامل64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
BACKGROUND The purpose of this study was to determine whether brain metastases from HER2-positive breast cancer could be detected noninvasively using positron emission tomography (PET) with (64)Cu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-trastuzumab. METHODS PET was performed on five patients with brain metastases from HER2-positive breast cancer, at 24 or 48 h after th...
متن کاملMulticenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
PURPOSE Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited and represents a major clinical challenge. Lapatinib, an epidermal growth factor receptor/HER2 inhibitor, was associated with regressions of CNS lesions in a small phase 2 trial. The...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2007
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-06-2478